Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie

Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. Clinical-stage immunotherapy company Alpine Immune S...
Streetwise Reports | June 19, 2020 |

Valeo Pharma In-Play, New HesperCo™ Immune System Support Scientifically Demonstrated

Shares of Valeo Pharma Inc. (CSE: VPH) (Frankfurt: VP2) poised for substantial upside revaluation to reflect the major ‘company –maker’ potential in HesperCo™ as the market figures out it is set to be the subject of Covid-19 clinical trial. Valeo will benefit...
Fredrick William | September 2, 2020 |

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

We are initiating coverage on INmune Bio Inc. (INMB:NASDAQ) . According to the company, INmune is "Reprogramming the Innate Immune System for the Treatment of Diseases." On the surface, this sounds like a fairly standard biotech tagline, but there's a more here than me...
Streetwise Reports | December 5, 2019 |

How BioVaxys' DPX platform creates anti-cancer immune response

Discover BioVaxys’ innovative DPX™ platform, a cutting-edge lipid-based delivery system transforming immunotherapy. This video explores how the company’s proprietary technology encapsulates diverse bioactive molecules, enhancing and sustai...
Research | October 8, 2024 |

Bellerophon Shares Take Off as FDA Grants Emergency Expanded Access for INOpulse for COVID-19 ...

Bellerophon Shares Take Off as FDA Grants Emergency Expanded Access for INOpulse for COVID-19 Treatment Shares of Bellerophon Therapeutics reached a new 52-week high price after the firm reported that the FDA granted emergency expanded access for its INOpulse®...
Streetwise Reports | March 23, 2020 |

Neon Therapeutics Shares Are Flashing Brightly after Reporting Predictive Cancer Breakthrough

After announcing publication in the scientific journal Immunity that it had created a 61-fold improvement process for predicting cancer-specific antigens, Neon Therapeutics' stock has traded wildly today, up more than 46% at times on nearly 100-times average daily volume, bu...
Streetwise Reports | September 9, 2019 |

Unique Value-Added Antiviral Vaccine Technology Platform

(Click to play video.) Founded in 2018 to improve on protein haptenization and leverage previous vaccine development in the field, Vancouver, BC-based BioVaxys Technology Corp . ( CSE.BIOV , OTCQB: BVAX , Forum ) is a clinical stage biotechnology company that...
Dave Jackson | September 14, 2021 |

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....
Streetwise Reports | October 4, 2019 |

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. Just a few days after reporting third quarter 2019 earnings, late-stage biotechnology company Iovance Biothe...
Streetwise Reports | November 12, 2019 |

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Shares of Regeneron Pharmaceuticals rose to a new 52-week high price after the company reported it has identified hundreds of virus-neutralizing antibodies and plans to initiate large-scale manufacturing by mid-April of a multi-antibody therapy to treat coronavirus. ...
Streetwise Reports | March 18, 2020 |
1 2 3 4 5 6 7 8 9 10 ...